Diabetic ketoacidosis secondary to growth hormone treatment in a boy with Prader-Willi syndrome and steatohepatitis.
A 13 year-old boy with Prader-Willi syndrome and steatohepatitis presented with diabetic ketoacidosis 4 weeks after the initiation of growth hormone (GH) treatment. He did not have signs or symptoms of type 2 diabetes mellitus (DM2) before the initiation of GH treatment. Hyperglycemia resolved 2 months after discontinuation of GH. He redeveloped DM2 6 months later associated with excessive weight gain. Diabetic ketoacidosis as a rare complication of GH therapy emphasizes the importance of screening for carbohydrate intolerance before and during GH treatment in patients with Prader-Willi syndrome. Steatohepatitis may be the only manifestation of insulin resistance and warrants further evaluation.
Yigit
Sevket
S
Department of Pediatric Endocrinology and Diabetes, Connecticut Children 's Medical Center, Hartford, CT 06119, USA.
Estrada
Elizabeth
E
Bucci
Karen
K
Hyams
Jeffrey
J
Rosengren
Sally
S
D000293:Adolescent; D003422:Critical Care; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D016883:Diabetic Ketoacidosis / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis; D004032:Diet; D004334:Drug Administration Schedule; D005234:Fatty Liver / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D005544:Forecasting; D013006:Growth Hormone / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D006760:Hospitalization; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced / Q000150:complications; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D011218:Prader-Willi Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D013997:Time Factors; D017211:Treatment Failure; D015430:Weight Gain
D007328:Insulin; D013006:Growth Hormone